"They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose
- PMID: 38413972
- PMCID: PMC10900746
- DOI: 10.1186/s12954-024-00964-5
"They make it too hard and too many hoops to jump": system and organizational barriers to drug treatment during epidemic rates of opioid overdose
Abstract
Introduction: The United States is currently facing an opioid overdose crisis. Research suggests that multiple interventions are needed to reduce overdose deaths including increasing access and retention to medications to treat opioid use disorders (MOUD, i.e., methadone, buprenorphine, and naltrexone) and increasing the distribution and use of naloxone, a medication that can reverse the respiratory depression that occurs during opioid overdoses. However, barriers to MOUD initiation and retention persist and discontinuations of MOUD carry a heightened risk of overdose. Many times, MOUD is not sought as a first line of treatment by people with opioid use disorder (OUD), many of whom seek treatment from medically managed withdrawal (detox) programs. Among those who do initiate MOUD, retention is generally low. The present study examines the treatment experiences of people who use opioids in three states, Connecticut, Kentucky, and Wisconsin.
Methods: We conducted in-depth interviews with people who use opioids in a rural, urban, and suburban area of three states: Connecticut, Kentucky and Wisconsin. Data analysis was collaborative and key themes were identified through multiple readings, coding of transcripts and discussion with all research team members.
Results: Results reveal a number of systemic issues that reduce the likelihood that people initiate and are retained on MOUD including the ubiquity of detox as a first step in drug treatment, abstinence requirements and requiring patients to attend group treatment. MOUD-related stigma was a significant factor in the kinds of treatment participants chose and their experiences in treatment.
Conclusions: Interventions to reduce MOUD stigma are needed to encourage MOUD as a first course of treatment. Eliminating abstinence-based rules for MOUD treatment may improve treatment retention and decrease overdose risk.
Keywords: Detox; Fentanyl; Heroin; Medically assisted withdrawal; Medications to treat opioid use disorder (MOUD); Opioid use disorder; Overdose; Polysubstance use.
© 2024. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Similar articles
-
"Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.J Subst Abuse Treat. 2022 Jul;138:108752. doi: 10.1016/j.jsat.2022.108752. Epub 2022 Feb 23. J Subst Abuse Treat. 2022. PMID: 35277306
-
Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: an effectiveness and cost-effectiveness analysis.Addiction. 2022 Sep;117(9):2450-2461. doi: 10.1111/add.15879. Epub 2022 Apr 12. Addiction. 2022. PMID: 35315162 Free PMC article.
-
Drug use patterns and factors related to the use and discontinuation of medications for opioid use disorder in the age of fentanyl: findings from a mixed-methods study of people who use drugs.Subst Abuse Treat Prev Policy. 2023 May 22;18(1):30. doi: 10.1186/s13011-023-00538-x. Subst Abuse Treat Prev Policy. 2023. PMID: 37217975 Free PMC article.
-
Access to Medications for Opioid Use Disorder and Associated Factors Among Adolescents and Young Adults: A Systematic Review.JAMA Pediatr. 2022 Mar 1;176(3):304-311. doi: 10.1001/jamapediatrics.2021.4606. JAMA Pediatr. 2022. PMID: 34870707 Free PMC article.
-
Payment-related barriers to medications for opioid use disorder: A critical review of the literature and real-world application.J Subst Use Addict Treat. 2024 Oct;165:209441. doi: 10.1016/j.josat.2024.209441. Epub 2024 Jun 19. J Subst Use Addict Treat. 2024. PMID: 38906417 Free PMC article. Review.
Cited by
-
Bivalent Hapten Display Strategies for Conjugate Vaccines Targeting Opioid Mixtures Containing Fentanyl.Bioconjug Chem. 2025 Apr 16;36(4):676-687. doi: 10.1021/acs.bioconjchem.4c00548. Epub 2025 Mar 16. Bioconjug Chem. 2025. PMID: 40091228
-
An approach designed to fail deaf children and their parents and how to change it.Harm Reduct J. 2024 Jul 10;21(1):132. doi: 10.1186/s12954-024-01039-1. Harm Reduct J. 2024. PMID: 38987778 Free PMC article. Review.
-
Scaling up medications for opioid use disorder in Kentucky: Qualitative perspectives of treatment organizations.Res Sq [Preprint]. 2024 Dec 12:rs.3.rs-5440415. doi: 10.21203/rs.3.rs-5440415/v1. Res Sq. 2024. Update in: Subst Abuse Treat Prev Policy. 2025 Apr 02;20(1):15. doi: 10.1186/s13011-025-00644-y. PMID: 39711557 Free PMC article. Updated. Preprint.
-
Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study.Drug Alcohol Depend. 2025 Mar 1;268:112586. doi: 10.1016/j.drugalcdep.2025.112586. Epub 2025 Jan 29. Drug Alcohol Depend. 2025. PMID: 39899919
-
Assessing experts' perspectives on challenges in substance misuse prevention, harm reduction, and treatment to shape funding priorities in New York State.Harm Reduct J. 2024 Jul 15;21(1):134. doi: 10.1186/s12954-024-01045-3. Harm Reduct J. 2024. PMID: 39004729 Free PMC article.
References
-
- Centers for Disease Control and Prevention. Opioid overdose: Understanding the epidemic. 2020.
-
- NCHS NVSS. Provisional drug overdose death counts; 2022.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical